Search

Your search keyword '"Gabriel N. Mannis"' showing total 3 results
Start Over Author "Gabriel N. Mannis" Journal bone marrow transplantation
3 results on '"Gabriel N. Mannis"'

2. Advance care planning and end-of-life care for patients with hematologic malignancies who die after hematopoietic cell transplant

Author

Lisa M. McNey, Derek Galligan, Kelly L. Schoenbeck, Gabriel N. Mannis, E E Eckhert, and Jimmy Hwang

Subjects
Advance care planning, Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Hematopoietic stem cell transplantation, 03 medical and health sciences, Advance Care Planning, 0302 clinical medicine, Medicine, Humans, 030212 general & internal medicine, Progenitor cell, Intensive care medicine, Aged, Retrospective Studies, Transplantation, Terminal Care, Hematopoietic cell, business.industry, Hematopoietic Stem Cell Transplantation, Retrospective cohort study, Hematology, Middle Aged, medicine.disease, Allografts, surgical procedures, operative, Graft-versus-host disease, 030220 oncology & carcinogenesis, Hematologic Neoplasms, Female, business, End-of-life care, Delivery of Health Care
Abstract

Advance care planning and end-of-life care for patients with hematologic malignancies who die after hematopoietic cell transplant

Published
2017

3. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis

Author

Claire Greene, Thomas G. Martin, Nobuhiko Emi, Anuj Mahindra, Jeffrey L. Wolf, Andrew D. Leavitt, Rebecca L. Olin, Gabriel N. Mannis, Yasuhiko Miyazaki, Peter H. Sayre, Lawrence D. Kaplan, Aaron C Logan, Tomoki Naoe, Jimmy Hwang, Karin M.L. Gaensler, Weiyun Z. Ai, Neel K. Gupta, Shigeki Ohtake, Jeffrey M. Venstrom, Catherine C. Smith, Masamitsu Yanada, Charalambos Andreadis, Lizette Caballero, and Lloyd E. Damon

Subjects
Acute promyelocytic leukemia, Oncology, Adult, Male, medicine.medical_specialty, Adolescent, CD34, Antineoplastic Agents, Arsenicals, Arsenic Trioxide, Leukemia, Promyelocytic, Acute, Internal medicine, medicine, Humans, Progenitor cell, Autografts, Transplantation, Peripheral Blood Stem Cell Transplantation, Neutrophil Engraftment, business.industry, Graft Survival, Oxides, Hematology, Middle Aged, medicine.disease, Surgery, Leukemia, Graft-versus-host disease, Female, Stem cell, business
Abstract

A potential link between arsenic (ATO)-based therapy and delayed hematopoietic recovery after autologous hematopoietic SCT (HSCT) for acute promyelocytic leukemia (APL) has previously been reported. We retrospectively reviewed the clinical histories of 58 patients undergoing autologous HSCT for APL at 21 institutions in the United States and Japan. Thirty-three (56%) of the patients received ATO-based therapy prior to stem cell collection. Delayed neutrophil engraftment occurred in 10 patients (17%): 9 of the 10 patients (90%) received prior ATO (representing 27% of all ATO-treated patients), compared with 1 of the 10 patients (10%) not previously treated with ATO (representing 4% of all ATO-naive patients; P

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results